Stockscreener 앱 받기
5.65
7.38%
-0.45
시간 외 거래:
5.65
전일 마감가:
$6.10
열려 있는:
$5.1
하루 거래량:
5.05M
Relative Volume:
2.44
시가총액:
$561.06M
수익:
$98.99M
순이익/손실:
$-197.98M
주가수익비율:
-2.8226
EPS:
-2.0017
순현금흐름:
$-175.32M
1주 성능:
-8.28%
1개월 성능:
-25.76%
6개월 성능:
-36.16%
1년 성능:
-60.95%
1일 변동 폭
$5.00
$5.84
1주일 범위
$5.00
$6.19
52주 변동 폭
$4.9102
$15.09
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
5.65 | 600.78M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | Northland Capital | Outperform |
| 2025-11-04 | 재개 | Roth Capital | Buy |
| 2025-09-04 | 개시 | Roth Capital | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
SPRY Slides As CVS Caremark Delay Triggers Class Action Hit - timothysykes.com
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
(SPRY) Volatility Zones as Tactical Triggers - Stock Traders Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down on Disappointing Earnings - marketbeat.com
Attention Long-Term Shareholders of ARS Pharmaceuticals, - GlobeNewswire
ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ... By GuruFocus - Investing.com Canada
ARS Pharmaceuticals earnings missed by $0.13, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals Q2 2026 Earnings Call Transcript - marketbeat.com
ARS Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ - The National Law Review
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action DeadlineContact the Firm Before October 5, 2026 - The Globe and Mail
ARS Pharmaceuticals (NASDAQ:SPRY) Posts Earnings Results, Misses Expectations By $0.15 EPS - marketbeat.com
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results - Investing News Network
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - aol.com
ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: ARS Pharmaceuticals shares fall after Q2 2026 report - Investing.com
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure ... - Caledonian Record
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
ARS PHARMACEUTICALS ($SPRY) Releases Q2 2026 Earnings - quiverquant.com
ARS Pharma Q2 Results: Revenue up 114% YoY, net loss widens - scanx.trade
ARS Pharmaceuticals (Nasdaq: SPRY) doubles Q2 2026 revenue but posts larger loss - Stock Titan
Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY - TMX Newsfile
SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026 - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - PR Newswire
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ARS Pharmaceuticals, Inc. (SPRY) - TMX Newsfile
Hennion & Walsh Asset Management Inc. Acquires Shares of 175,614 ARS Pharmaceuticals, Inc. $SPRY - marketbeat.com
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against ARS Pharmaceuticals, Inc. ... - Caledonian Record
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
SPRY UPCOMING DEADLINE: Levi & Korsinsky Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earnings - Yahoo Finance
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earni - GuruFocus
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
SPRY Investors with Losses in Excess of $100K Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Sahm
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights - Barchart.com
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ARS Pharmaceuticals Investors Face October Lawsuit Deadline - stl.news
SPRY DEADLINE: The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline - YCharts
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit ... - Caledonian Record
Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors - GlobeNewswire
SPRY DEADLINE: Levi & Korsinsky Reminds ARS Pharmaceuticals - GlobeNewswire
ARS PHARMACEUTICALS LAWSUIT ALERT: Bragar Eagel & Squire, - GlobeNewswire
SPRY Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against ARS Pharmaceuticals Inc. - Morningstar
SPRY Deadline Alert: The Gross Law Firm Reminds ARS - GlobeNewswire
First Trust Advisors LP Purchases New Shares in ARS Pharmaceuticals, Inc. $SPRY - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceu - The National Law Review
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. LawsuitSPRY - PR Newswire
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):